OR WAIT null SECS
Mylan signed a sub-license agreement with the Medicines Patent Pool to develop a generic version of daclatasvir to market in developing countries.
On Nov. 28, 2016, Mylan NV announced that they have signed an agreement with the Medicines Patent Pool (MPP) to expand access to chronic hepatitis C medicines in developing countries. The agreement licenses Mylan to produce and market a generic version of Bristol-Myers Squibb’s Daklinza (daclatasvir) tablets, 30 mg and 60 mg, for distribution in low- and middle-income countries.
Daclatasvir tablets, 30 mg and 60 mg, are indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus genotype 1 or genotype 3 infection in the United States and genotype 1, 3, and 4 in Europe. The license allows Mylan to develop fixed-dose combinations that offer the potential to treat the six major genotypes of the hepatitis C virus. Earlier this year, the World Health Organization added several new hepatitis C treatments, including daclatasvir, to its essential medicines list, Mylan said in a press statement.